Pakistan's Private Vaccinations Draw Criticism
NY Times
MAY 22, 2021
An inoculation push, plagued with limited supplies and red tape, makes doses available to those who can pay for them. In a country with a struggling economy, most can’t.
NY Times
MAY 22, 2021
An inoculation push, plagued with limited supplies and red tape, makes doses available to those who can pay for them. In a country with a struggling economy, most can’t.
Druggist
MAY 22, 2021
Gaviscon is (most likely) the most well-known brand of liquid antacid. Antacids are used to relieve symptoms of heartburn and indigestion (dyspepsia). Heartburn is a common symptom experienced during pregnancy. Today I will look into the use of Gaviscon in pregnancy by looking at the main recommendations of heartburn treatment in pregnancy. I will conclude which particular Gaviscon product is the best to use in the pregnancy. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NY Times
MAY 22, 2021
Mr. Hanly had been central to the current nationwide litigation against pharmaceutical companies, pharmacies and others in the opioid supply chain.
Drug Patent Watch
MAY 22, 2021
ZOMIG (zolmitriptan) Astrazeneca Patent: 7,220,767 Expiration: May 28, 2021 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit…. The post Drug Patent Expirations for the Week of May 23, 2021 appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
NY Times
MAY 22, 2021
The Big Pharma drug model is inefficient and unsustainable. There is an alternative.
BioTech 365
MAY 22, 2021
Humacyte Announces Presentation by Principal Investigator Highlighting Clinical Experience with HAVs at Vascular Access Society of the Americas 2021 Spring Conference Humacyte Announces Presentation by Principal Investigator Highlighting Clinical Experience with HAVs at Vascular Access Society of the Americas 2021 … Continue reading →
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioTech 365
MAY 22, 2021
Moderna and South Korea Explore Collaboration on mRNA Vaccines Moderna and South Korea Explore Collaboration on mRNA Vaccines Moderna and South Korea will explore potential areas of collaboration for research and development of mRNA vaccines and local manufacturing opportunities in … Continue reading →
BioTech 365
MAY 22, 2021
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results ? Takeda’s dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.
BioTech 365
MAY 22, 2021
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine The agreement will further enable global supply of mRNA-1273, Moderna’s COVID-19 vaccine with Samsung … Continue reading →
BioTech 365
MAY 22, 2021
HumanOptics AG / Key word(s): Squeeze Out HumanOptics AG: Cash compensation for merger squeeze-out determined at EUR 8.71 per share 22-May-2021 / 18:14 CET/CEST Disclosure of an inside information acc.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioTech 365
MAY 22, 2021
Ferring and Rebiotix Present Positive Interim Phase 3 Results From Open-Label Study of Investigational Microbiota-Based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) Ferring and Rebiotix Present Positive Interim Phase 3 Results From Open-Label Study of Investigational Microbiota-Based Live Biotherapeutic … Continue reading →
BioTech 365
MAY 22, 2021
Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology Lead Therapeutic Targeting the Main Source of Cortisol Toxicity to be Studied in Phase 2 Trial … Continue reading →
Let's personalize your content